Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.67. Xtant Medical shares last traded at $0.61, with a volume of 25,953 shares traded.
Analysts Set New Price Targets
Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the stock a "buy" rating in a report on Friday, October 18th.
View Our Latest Analysis on Xtant Medical
Xtant Medical Stock Down 3.6 %
The firm has a market capitalization of $80.63 million, a price-to-earnings ratio of -4.46 and a beta of 0.35. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last issued its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $27.94 million during the quarter. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%.
Hedge Funds Weigh In On Xtant Medical
A hedge fund recently bought a new stake in Xtant Medical stock. Evernest Financial Advisors LLC bought a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 40,000 shares of the medical device company's stock, valued at approximately $27,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
